Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tetrapeptide
Cardiogen is a marketed name for the tetrapeptide AEDR, studied mainly in cardiovascular cells and animal models.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Cardiogen is a marketed name for AEDR, a four-amino-acid peptide. Research has focused mainly on cardiovascular cells, organ-specific signaling ideas, and animal models.
Short peptide sequences are studied to see whether they alter cell behavior or tissue-related markers. For Cardiogen, researchers have also explored growth and tumor questions relevant to safety.
Laboratory, animal, and review-level records describe cardiovascular and growth-related hypotheses. One rat tumor study examined AEDR in a preclinical safety context. Relay found no controlled administered-human study establishing heart function, symptoms, clinical outcomes, or safety.
Human absorption, pharmacokinetics, target engagement, cardiovascular benefit, rhythm and blood-pressure effects, tumor-related implications, product identity, interactions, and long-term safety remain unknown. Organ-specific naming does not establish organ-specific action in people.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published research investigated AEDR in a controlled rat tumor model to explore growth-related questions around the peptide's preclinical biology.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Laboratory and animal evidence; no controlled administered-human efficacy study located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified controlled administered-human Cardiogen study was located. A rat tumor experiment cannot establish human cardiovascular benefit, cancer risk, pharmacology, or safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
No controlled administered-human Cardiogen study was located.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
AEDR experiments explore gene-expression, cell-growth, and tissue effects. The available record does not establish a human cardiovascular treatment.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled animal tumor study
Rats
Endpoints were not fully described in the current record.
AEDR was evaluated in an animal tumor model to explore growth-related safety questions.
Study administration: Not stated in the current record.
Limitations: Does not establish human cancer risk or cardiovascular benefit.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
A review summarizes mostly laboratory and animal work on organ-specific peptide hypotheses.
Study administration: Not stated in the current record.
Limitations: Review and mechanistic evidence do not replace direct clinical trials.
Safety snapshot
Current evidence cannot yet resolve: Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryPreclinical; no FDA-approved Cardiogen/AEDR product. Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 20396706
PMID 34830335